InnoCan Pharma Management
Management criteria checks 4/4
InnoCan Pharma's CEO is Iris Bincovich, appointed in Jan 2018, has a tenure of 6.92 years. total yearly compensation is $337.00K, comprised of 79.5% salary and 20.5% bonuses, including company stock and options. directly owns 1.8% of the company’s shares, worth $664.45K. The average tenure of the management team and the board of directors is 5.4 years and 5.1 years respectively.
Key information
Iris Bincovich
Chief executive officer
US$337.0k
Total compensation
| CEO salary percentage | 79.5% |
| CEO tenure | 6.9yrs |
| CEO ownership | 1.8% |
| Management average tenure | 5.4yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$3m |
| Jun 30 2024 | n/a | n/a | -US$4m |
| Mar 31 2024 | n/a | n/a | -US$5m |
| Dec 31 2023 | US$337k | US$268k | -US$5m |
| Sep 30 2023 | n/a | n/a | -US$5m |
| Jun 30 2023 | n/a | n/a | -US$3m |
| Mar 31 2023 | n/a | n/a | -US$4m |
| Dec 31 2022 | US$401k | US$291k | -US$4m |
| Sep 30 2022 | n/a | n/a | -US$3m |
| Jun 30 2022 | n/a | n/a | -US$7m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$645k | US$300k | -US$10m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$14m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$361k | US$223k | -US$10m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | -US$5m |
| Mar 31 2020 | n/a | n/a | -US$3m |
| Dec 31 2019 | US$384k | US$219k | -US$3m |
| Sep 30 2019 | n/a | n/a | -US$6m |
| Dec 31 2018 | US$165k | US$54k | -US$2m |
Compensation vs Market: Iris's total compensation ($USD337.00K) is below average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Iris's compensation has been consistent with company performance over the past year.
CEO
Iris Bincovich (54 yo)
6.9yrs
Tenure
US$337,000
Compensation
Mrs. Iris Bincovich has been Member of Advisory Board at Ayurcann Holdings Corp. since May 2021. Mrs. Bincovich has been the Chief Executive Officer at InnoCan Pharma Corporation since January 2018 and has...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 5.3yrs | US$136.00k | 2.29% $ 845.2k | |
| CEO & Director | 6.9yrs | US$337.00k | 1.8% $ 664.4k | |
| Chief Financial Officer | 5.8yrs | US$64.00k | 0.11% $ 39.1k | |
| COO & CEO of BI Sky Global and Director | 2.3yrs | US$230.00k | 0.15% $ 57.2k | |
| Director & Company Secretary | 4.9yrs | no data | 0.89% $ 328.7k | |
| Founder & Executive VP of Business Development | no data | US$173.00k | no data |
5.4yrs
Average Tenure
58yo
Average Age
Experienced Management: INNP.F's management team is seasoned and experienced (5.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 5.3yrs | US$136.00k | 2.29% $ 845.2k | |
| CEO & Director | 5.3yrs | US$337.00k | 1.8% $ 664.4k | |
| COO & CEO of BI Sky Global and Director | less than a year | US$230.00k | 0.15% $ 57.2k | |
| Director & Company Secretary | 5.3yrs | no data | 0.89% $ 328.7k | |
| Member of Advisory Committee | 3.4yrs | no data | no data | |
| Independent Director | 4.9yrs | no data | 0% $ 0 | |
| Member of Scientific Advisory Board | 1.3yrs | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 5.3yrs | no data | 0.071% $ 26.2k | |
| Director | 5.3yrs | no data | 0.11% $ 40.3k | |
| Scientific Advisor | no data | no data | no data | |
| Member of Scientific Advisory Committee | 3.8yrs | no data | no data |
5.1yrs
Average Tenure
54yo
Average Age
Experienced Board: INNP.F's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 11:30 |
| End of Day Share Price | 2024/12/09 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InnoCan Pharma Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|